Bristol-Myers Squibb: Key Facts

Key Facts

Chief Executive Officer:
Giovanni Caforio, M.D.
New York City
Web Address:
NYSE Listing:
Net Sales:
$16.6 billion in 2015
R&D Investment:
$4.04 billion which included the discovery and development of new medicines for patients
2015 Largest-Selling Products:
ORENCIA®, $1.9 billion
ELIQUIS®, $1.9 billion
SPRYCEL®, $1.6 billion
Hepatitis C franchise, $1.6 billion
BARACLUDE®, $1.3 billion
SUSTIVA® franchise, $1.3 billion
REYATAZ® franchise, $1.1 billion
YERVOY®, $1.1 billion
OPDIVO®, $942 million
Selected Key Products:
BARACLUDE® (entecavir)
DAKLINZA™ (daclatasvir)
ELIQUIS® (apixaban)
EMPLICITI™ (elotuzamab)
OPDIVO® (nivolumab)
ORENCIA® (abatacept)
REYATAZ® (atazanavir sulfate)
SPRYCEL® (dasatinib)
SUSTIVA® (efavirenz)
YERVOY® (ipilimumab)
Principal Locations:
Worldwide Facilities

Please click on the product links to see the Full Prescribing Information for BARACLUDE®, DAKLINZA™, ELIQUIS®, EMPLICITI™, OPDIVO®, ORENCIA®, REYATAZ®, SPRYCEL®, SUSTIVA®, and YERVOY®, including Boxed WARNINGS for BARACLUDE®, ELIQUIS®, and Boxed WARNINGS for YERVOY® regarding immune-mediated adverse reaction.

February, 2016


You are leaving to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.